Priority Lists
Protocol Posting of
Activations
Closures
Permanent Closure
A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma.
| Study Coordinator(s) | Carolyn M. Johnston, M.D. |
| Participants | Members, NCORP |
| Closure Date | 2003-08-15 |
Permanent Closure
Phase II Trial of Irinotecan (Camptosar) for Patients with Platinum and Taxane Refractory Ovarian, Peritoneal or Fallopian Tube Cancer
| Study Coordinator(s) | Amy D. Tiersten, M.D., William R. Robinson, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
| Closure Date | 2003-08-15 |
Permanent Closure
Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix
| Study Coordinator(s) | Harry Long, M.D., Maurie Markman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, CTSU |
| Closure Date | 2003-07-28 |
Amendments, Revisions, Memoranda
A Comparative Randomized Study of Standard Doxorubicin And Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin And Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory And Locally Advanced Breast Cancer
| Study Coordinator(s) | Georgiana K. Ellis, M.D., Robert B. Livingston, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists, EPP, CTSU |
Revision #1
Protocol for Assessment of Capecitabine for Advanced Colorectal Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger than 60 Years)
| Study Coordinator(s) | Heinz- Josef Lenz, M.D., Derek Raghavan, M.D.,Ph.D., Carolyn C. Gotay, Ph.D., Dorothy Coleman, R.N., M.S. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, Who Have The Ability To Perform Outpatient Blood Collections For Pharmacology Studies |
Revision #18
Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III
| Study Coordinator(s) | Maha H.A. Hussain, M.D., Celestia S. Higano, M.D., Brian J. Miles, M.D., Paul H. Lange, M.D., E. David Crawford, M.D., Donna L. Berry, R.N.,Ph.D., Carol M. Moinpour, Ph.D. |
| Participants | Members, NCORP, UCOP, Affiliates, Medical Oncologists, Surgeons, Pathologists, CALGB, ECOG, EORTC, EPP, NCIC-CTG |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required